EyePoint Pharmaceuticals (EYPT) 10-K2024 FY Annual report

Filed: 6 Mar 25, 4:05pm

Content analysis

Positive
Negative
Uncertain
Constraining
Legalese
Litigious
Readability	H.S. junior Avg

New words: AFL, AI, anatomy, ancillary, anti, Apptec, ARF, artificial, bilateral, BIOSECURE, budgetary, built, catastrophic, CDMO, CMO, CODM, compensatory, dataset, DAYBREAK, disaggregated, Disaggregation, dislodged, Donald, dual, DURAVYU, duravyu™, Efficiency, environmental, esteemed, ethical, EURetina, explained, Eyebio, Eyebiotech, EYLEA®HD, feedback, foot, Forum, Fred, freeze, grand, guest, hampered, Hassan, headcount, hosted, immediacy, KOL, lot, LUCIA, LUGANO, machine, Marcia, meaningfully, mentioned, Mexico, MOA, multilateral, needy, Notwithstanding, oBCVA, oCST, Olon, oNo, oPhase, oPositive, Opuviz, oThe, payload, PIGF, pioneer, presidential, Rally, ranibizimab, rectified, redosing, reginald, renowned, resigned, retaliatory, RNAi, SHORE, short, shutdown, solidify, Spain, SPC, strain, struggle, sunset, tariff, transgene, Trap, Trump, unconjugated, underscoring, unexplained, unintended, unintentionally, unstable, upper, USA, WuXi, Yesafili, York

Removed: abnormally, accelerate, accumulation, accumulator, affirmative, ambulatory, annum, appointed, ASD, beading, billion, bleeding, blended, bore, borrower, cloud, cognitive, context, corneal, CRG, denoted, deposit, dilated, discomfort, divided, earthquake, employ, formal, fourth, front, fulfilment, goodwill, grew, hard, harmonized, inferior, intangible, intraretinal, IOP, IRMA, irreversible, Israel, kitting, lipid, locally, manager, mandate, mark, McKesson, microvascular, migration, mild, minimal, moderate, NMPA, organized, outbreak, owed, painful, PDR, peripheral, prepayment, presence, prime, problem, proceed, progressive, proliferative, prorated, purported, repay, rescue, revealed, revolving, scheduled, score, secured, Servicing, shipped, shortfall, simplify, steady, sterilization, streamline, streamlined, subjectivity, text, thicker, tissue, undiscounted, unpaid, unpartnered, verisome, vessel, wall, yellow

Search this filing

Filing tables

Export all tables to Excel

Filing exhibits

Related press release

Associated EYPT transcripts

EYPT similar filings

Filing view

Default size S M L
Default font Times Arial

External links

Share this filing

Exhibit 32.1

Certification of Principal Executive Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.

In connection with the Annual Report of EyePoint Pharmaceuticals, Inc. (the “Company”) on Form 10-K for the twelve months ended December 31, 2024, as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I, Jay S. Duker, President and Chief Executive Officer of the Company, certify that to the best of my knowledge:

1. The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

2. The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

Date: March 6, 2025

/s/ Jay S. Duker

Name: Jay S. Duker, M.D.

Title: President and Chief Executive Officer

(Principal Executive Officer)